Suppressing MDSC Recruitment to the Tumor Microenvironment by Antagonizing CXCR2 to Enhance the Efficacy of Immunotherapy

SIMPLE SUMMARY: While the development of immunotherapy has greatly advanced cancer treatment, many patients do not benefit from immunotherapy. Numerous strategies have been developed to improve response to immunotherapy across cancer types, including blocking the activity of immunosuppressive immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Bullock, Kennady, Richmond, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699249/
https://www.ncbi.nlm.nih.gov/pubmed/34944914
http://dx.doi.org/10.3390/cancers13246293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699249/
https://www.ncbi.nlm.nih.gov/pubmed/34944914
http://dx.doi.org/10.3390/cancers13246293

Ejemplares similares